The risk of tuberculosis in patients treated with TNF antagonists. - Wikidata - awgldk - TriplyDB

The risk of tuberculosis in patients treated with TNF antagonists.

The risk of tuberculosis in patients treated with TNF antagonists.

http://www.wikidata.org/entity/Q37877262

about

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis An Investigation into the Immunomodulatory Activities of Sutherlandia frutescens in Healthy Mice.Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor.Anti-Inflammatory Effects of the Essential Oils of Ginger (Zingiber officinale Roscoe) in Experimental Rheumatoid Arthritis.BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats.A systematic review of biologics for the treatment of noninfectious uveitis.HLA-B27 Anterior Uveitis: Immunology and Immunopathology.[Guidelines for vaccination of immunocompromised individuals].Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis.

P2860

Q26991673-17AD9D70-027A-4BB2-A703-AE8961621A34 Q30799235-4D1A10EF-00D1-4267-A7A3-6631009CC14C Q36038705-B95AE814-335F-401B-A437-87F98BB18877 Q36116696-297B19B0-E76B-41C6-B809-6EC63FC9D94A Q36585653-A69B92AE-CFA5-4EE9-A948-AFE777C8FABB Q36705704-6585AF35-9BBA-4136-9B2D-B374938738A3 Q37423376-AEE59668-4ECC-49B7-BC4F-4CE309A0A9C4 Q37728305-B20DC0C3-955D-4CBC-8319-53734B3CCC76 Q38068969-8E59131C-34F1-4B6E-A9E6-B0E0351B6A64 Q38849274-F693067C-EB60-4D52-B96F-4AE6C0EF2F4A Q40600058-DAD23B2B-E45A-4C37-BB8C-84DD6963A0B4 Q42242252-923D05BF-9A62-412D-8C39-0B89274770AA

P2860

The risk of tuberculosis in patients treated with TNF antagonists.

http://www.wikidata.org/entity/Q37877262

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The risk of tuberculosis in patients treated with TNF antagonists.

@en

The risk of tuberculosis in patients treated with TNF antagonists.

@nl

type

label

The risk of tuberculosis in patients treated with TNF antagonists.

@en

The risk of tuberculosis in patients treated with TNF antagonists.

@nl

prefLabel

The risk of tuberculosis in patients treated with TNF antagonists.

@en

The risk of tuberculosis in patients treated with TNF antagonists.

@nl

P1433

Q37877262-7B2F4BF9-FE5F-493A-8D3D-AC45BD89F69D

P1476

Q37877262-EE4758C8-17DB-4180-AB79-CA2DC8AB3B90

P2093

Q37877262-A3863C7A-7C0E-4AF0-9D6E-ED194267BB76

Q37877262-BBA519EA-1FF0-4EF8-8EC4-6F4F9D79949C

P2860

Q37877262-040667D3-5565-4A31-AF35-FC37F40F4797

Q37877262-0538C74F-B2E2-447C-9949-8C91D77E5829

Q37877262-0A527235-A641-46DD-A348-C1F34ED143DB

Q37877262-0A5CBB51-38D2-4A26-AE18-2C06180910B8

Q37877262-110618FE-DEFE-41E4-83E3-845365DA96DE

Q37877262-1AB5D1DF-474D-4DF7-BCDB-E6A642B95FB9

Q37877262-2137A4A9-0F3A-45B8-9556-62C335349D5F

Q37877262-2227460C-CD3F-40C7-A9A8-CA2C1F3B1262

Q37877262-22ED4303-764C-44A6-8076-490967EECC5B

Q37877262-2DC86E16-E0AD-4C2D-8C71-AE89AE3C12F7

P304

Q37877262-323B40E6-5DA0-4C37-8818-9146C47D09B6

P31

Q37877262-AFC1869F-2077-4B15-8D3E-4DA88E8EE846

P356

Q37877262-941CCCAD-EDFC-4955-A81B-00BEA0354BBA

P433

Q37877262-FF04D968-42A2-4A71-8933-9AF1631905F5

P478

Q37877262-87C2A6E4-5D6E-4F4A-8B8A-613C5D786DAA

P577

Q37877262-A1C17E03-0858-4900-B62A-BE33750033EE

P698

Q37877262-75943B1E-C152-45EE-9D6E-622BF49D9CC9

P921

Q37877262-1BB21D74-2F43-4250-AD3A-5D859E4ED080

Q37877262-7FCC2758-3051-42C9-A50C-B7B789E3AB60

P356

P1433

Expert Review of Clinical Immunology

P1476

The risk of tuberculosis in patients treated with TNF antagonists.

@en

P2093

Eva Salgado

http://www.w3.org/2001/XMLSchema#string

Juan J Gómez-Reino

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Infliximab for induction and maintenance therapy for ulcerative colitis

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

P304

329-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.11.6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21595599

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde